Drug Profile
Pidnarulex - Senhwa Biosciences
Alternative Names: CX-5461Latest Information Update: 19 Dec 2023
Price :
$50
*
At a glance
- Originator Cylene Pharmaceuticals
- Developer BC Cancer Research Centre; Canadian Cancer Trials Group; Peter MacCallum Cancer Centre; Senhwa Biosciences
- Class Amides; Antineoplastics; Heterocyclic compounds with 4 or more rings; Pyrazines; Small molecules; Thiazoles
- Mechanism of Action G-Quadruplex modulators; RNA polymerase I inhibitors; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Haematological malignancies; Ovarian cancer
- Phase I/II Solid tumours
- Phase I Prostate cancer
Most Recent Events
- 11 Dec 2023 Peter MacCallum Cancer Centre suspended the enrollment in the phase I trial in Prostate cancer in order to further assess supplementary non-clinical study data
- 18 Jan 2023 Senhwa Biosciences and Canadian Cancer Trials Group completes a phase I trial in Solid tumours (Late Stage) in Canada (IV) (NCT02719977)
- 21 Oct 2022 Phase-I clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in Australia (IV) (NCT05425862)